目前，18 F-氟脱氧葡萄糖正电子发射计算机断层扫描（PET/CT）显像在B-细胞前体淋巴母细胞性淋巴瘤（BCP-LBL）的标准诊断中没有使用，并且目前尚不清楚PET/CT显像是否会导致与黄金标准显像方法在病变检测方面的一致性。因此，我们进行了一项回顾性队列研究，纳入32名小儿BCP-LBL患者，并通过审查当地显像报告确定病变定位。在59％的患者中，协议性显像和PET/CT之间存在不一致，主要包括PET/CT检测到的额外病变，通常在淋巴结和骨骼中或PET/CT中骨髓未受累。如果PET/CT在确定疾病确切分期方面具有主导作用，这将导致31％的患者疾病分期不同，并分别导致28％的患者选择不同的治疗分支。© 2023 Wiley Periodicals LLC。

18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) imaging is currently not used in standard diagnostics for B-cell precursor lymphoblastic lymphoma (BCP-LBL), and it is unknown whether PET/CT imaging would lead to agreement between detection of lesions with the gold standard imaging methods. Therefore, we performed a retrospective cohort study in which we included 32 pediatric BCP-LBL patients and determined localizations by reviewing local imaging reports. There was a disagreement between protocol-based imaging and PET/CT in 59% of the patients, and the discrepancies mostly comprise of additional lesions detected with PET/CT, typically in lymph node and bone or the absence of bone marrow involvement with PET/CT. If PET/CT was leading in determining definite stage of disease, this would lead to a different stage and therapy branch in 31% and 28% of the patients, respectively.© 2023 Wiley Periodicals LLC.